DWP
NBIX icon

Daymark Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Daymark Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$884K Buy
5,245
+28
+0.5% +$4.15K 0.02% 359
2026
Q1 		$687K Buy
5,217
+3,436
+193% +$456K 0.02% 355
2025
Q4 		$253K Sell
1,781
-127
-7% -$18.4K 0.01% 530
2025
Q3 		$268K Sell
1,908
-37
-2% -$5.01K 0.01% 510
2025
Q2 		$244K Buy
+1,945
New +$223K 0.01% 493
2025
Q1 		– Sell
-1,786
Closed -$244K – 520
2024
Q4 		$244K Buy
+1,786
New +$221K 0.01% 450
2024
Q3 		– Sell
-1,774
Closed -$244K – 523
2024
Q2 		$244K Buy
1,774
+274
+18% +$37.6K 0.01% 444
2024
Q1 		$207K Buy
+1,500
New +$205K 0.01% 412

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Daymark Wealth Partners's NBIX Position: Q2 2026 in Review

Daymark Wealth Partners increased its Neurocrine Biosciences (NBIX) stake by 0.54% in Q2 2026, buying an estimated $4.15K and bringing the position to 5,245 shares worth $884K. The position accounts for 0.02% of the portfolio, ranked #359.

Daymark Wealth Partners first reported a position in NBIX in Q1 2024 and has held it in 8 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Daymark Wealth Partners held 5,245 shares of Neurocrine Biosciences worth $884K as of Q2 2026.
  • Daymark Wealth Partners bought 28 Neurocrine Biosciences shares in Q2 2026, an estimated $4.15K.
  • Neurocrine Biosciences made up 0.02% of Daymark Wealth Partners's portfolio in Q2 2026, its #359 holding.
  • Daymark Wealth Partners first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 8 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.